COMPOSITION:
Each film-coated tablet contains Daraxonrasib ……………………………………… 150 mg.
INDICATION:
LuciDarax 150 mg is a RAS(ON) inhibitor indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy.
DOSAGE AND USE:
The recommended total daily dose of LuciDarax is 300 mg administered orally once daily with or without food, which corresponds to two 150 mg tablets taken together once daily. Swallow tablets whole with water; do not crush, chew, or split. Take at approximately the same time each day to maintain a consistent routine. If more than 4 hours have passed since a missed dose, skip it and take the next dose at the usual time. Do not double the dose. If vomiting occurs after taking the tablets, do not take additional tablets; continue with the next scheduled dose.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of reach of Children. Do not administer LuciDarax during Pregnancy and Lactation. LuciDarax may cause fetal harm. Pregnancy should be excluded before starting treatment in females who can become pregnant. Effective contraception is recommended during treatment and for 1 week after the last dose for females and for males with partners who can become pregnant. Breastfeeding is not recommended during treatment and for 1 week after the final dose. The safety and effectiveness of LuciDarax have not been established in pediatric patients. Contact your healthcare team promptly if you develop severe or persistent diarrhea, significant mouth sores, new breathing difficulties, severe abdominal pain, or serious skin reactions. Do not stop or adjust treatment without medical guidance.
About LuciDarax 150 mg
LuciDarax 150 mg is an oral, targeted RAS(ON) inhibitor developed by Lucius Pharmaceuticals for eligible adults with metastatic pancreatic adenocarcinoma. The 150 mg strength is designed to simplify daily dosing: two tablets provide the recommended 300 mg total daily dose. This higher-strength format may help reduce the number of tablets taken each day, supporting convenience and adherence for patients on long-term therapy.
Why the 150 mg Strength?
- Simplified daily dosing — two tablets provide the standard 300 mg daily dose.
- Fewer tablets per day — may support convenience and treatment adherence.
- Consistent routine — taken once daily, with or without food.
- Targeted mechanism — inhibits the active RAS(ON) state involved in cancer-cell signaling.
How LuciDarax 150 mg Works
LuciDarax is a targeted RAS(ON) inhibitor that blocks active RAS proteins involved in cancer-cell signaling. In tumors driven by RAS mutations, particularly KRAS mutations, RAS can remain abnormally active and continuously transmit signals that promote cell growth, survival, and proliferation. By binding to the active RAS(ON) state, LuciDarax helps suppress downstream signaling pathways that support tumor growth and progression.
Frequently Asked Questions — LuciDarax 150 mg
Q1. What is LuciDarax 150 mg used for?
A: It is indicated for eligible adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy.
Q2. How many 150 mg tablets make the daily dose?
A: The recommended total daily dose is 300 mg, which corresponds to two 150 mg tablets taken once daily.
Q3. What is the advantage of the 150 mg strength?
A: The 150 mg strength allows the 300 mg daily dose to be taken as two tablets instead of three, which may simplify the daily routine for some patients.
Q4. Can LuciDarax 150 mg be taken with food?
A: Yes. It can be taken with or without food.
Q5. What should I do if I miss a dose?
A: If more than 4 hours have passed since the scheduled dose, skip it and take the next dose at the usual time. Do not double the dose.
Q6. What if I vomit after taking the tablets?
A: Do not take additional tablets. Continue with the next scheduled dose.
Q7. Can the dose be adjusted?
A: Your oncologist may adjust, interrupt, or discontinue treatment based on your response and side effects. Never change the dose on your own.
Q8. What side effects may occur?
A: Diarrhea, nausea, vomiting, abdominal discomfort, fatigue, decreased appetite, weight loss, skin reactions, dry skin, mouth sores, or swelling may occur. Contact your healthcare team if symptoms are severe or persistent.
Q9. Is LuciDarax 150 mg safe during pregnancy?
A: No. LuciDarax may cause fetal harm. Pregnancy should be excluded before treatment, and effective contraception is required during treatment and for 1 week after the last dose.
Q10. Can children take LuciDarax 150 mg?
A: The safety and effectiveness have not been established in pediatric patients.
Q11. Can I stop treatment if I feel better?
A: No. Treatment duration should be determined by your oncologist. Do not stop or adjust treatment without medical guidance.
Packaging
LuciDarax 150 mg is supplied as film-coated oral tablets. Please refer to the pack for the exact number of tablets per pack.
Need more flexible dose adjustment?
See LuciDarax 100mg (Daraxonrasib), where three tablets provide the 300 mg daily dose.
Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/lucidarax-150mg-daraxonrasib/
Related News
-
LuciTala Side Effects — Blood Count Changes and Clinical Trial Safety
Introduction Cancer medicines can affect patients in different ways. Some side effects…
2026-11-06
-
LuciTala Dosage and Administration — How to Take Talazoparib Safely
Introduction Taking an oral cancer medicine at home can be convenient, but…
2026-11-04
-
LuciTala (Talazoparib): How PARP Inhibition Works in Certain Cancers
Introduction A cancer diagnosis often brings difficult questions about treatment, expected outcomes…
2026-11-02
-
LuciNav Side Effects — Hyperglycaemia, Risks and Patient Monitoring
Introduction Targeted cancer medicines are designed to act on particular biological pathways,…
2026-10-31
-
How to Take LuciNav Safely — Dosage, Monitoring and Precautions
Introduction Taking an oral cancer medicine involves more than following a daily…
2026-10-26
-
LuciNav (Inavolisib) for PIK3CA-Mutated Breast Cancer
Introduction A breast cancer diagnosis can bring uncertainty, particularly when the disease…
2026-10-21



